查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611831

破傷風類毒素疫苗市場：按疫苗類型、年齡和最終用戶分類 - 全球預測 2025-2030

Tetanus Toxoid Vaccine Market by Vaccine Type (Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), Tetanus, Diphtheria and Pertussis (Tdap)), Age (Adults, Neonatal), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年破傷風類毒素疫苗市值為55.8億美元，預計2024年將達58.6億美元，複合年成長率為6.75%，到2030年將達到88.3億美元。

破傷風類毒素疫苗是一種重要的醫療產品，因其能夠預防破傷風，破傷風是一種以肌肉僵硬和痙攣為特徵的致命細菌感染疾病。這種疫苗的需求源於它在保護可能因割傷或受傷而接觸破傷風梭菌的人們方面的作用，特別是在醫療機構、軍隊以及開發中地區的分娩過程中。它的用途還擴展到各種公共衛生項目，其中常規免疫接種和加強注射至關重要。該疫苗的最終用途包括醫院、診所和社區健康保健服務，並大力推動擴大其在低收入和中等收入國家的使用。目前的破傷風類毒素疫苗市場受到全球疫苗接種意識不斷增強、政府支持性免疫計畫以及給藥技術進步等因素的影響。預防多種疾病的組合疫苗正在引起人們的關注，為製造商創新和應對不同的人口趨勢鋪平了道路。然而，它面臨著挑戰​​，包括疫苗交付的物流問題、偏遠地區缺乏認知以及某些人群對接種疫苗猶豫不決。此外，在對負擔得起的醫療保健解決方案的需求中，監管障礙和定價壓力正在限制市場。儘管有這些挑戰，但仍有創新空間的領域包括單劑疫苗、改進的低溫運輸技術以及數位控制的輸送系統，以提高效率和疫苗接種率。在公共衛生優先事項以及與非政府組織合作以提高疫苗接種覆蓋率的推動下，市場傾向於穩定和有彈性的成長模式。公司可以透過投資教育宣傳活動和開發更具成本效益、更容易管理、更容易獲得公眾接受的疫苗而受益。

主要市場統計
基準年[2023] 55.8億美元
預計年份 [2024] 58.6億美元
預測年份 [2030] 88.3億美元
複合年成長率（%） 6.75%

市場動態：快速發展的破傷風類毒素疫苗市場的關鍵市場洞察

破傷風類毒素疫苗市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球破傷風流行率高
    • 破傷風疫苗的成本更低且供應範圍更廣
  • 市場限制因素
    • 因疫苗品質缺陷而導致產品召回的可能性
  • 市場機會
    • 政府為提高意識和疫苗接種計劃所做的努力
    • 改善各國的低溫運輸和醫療基礎設施
  • 市場挑戰
    • 與疫苗相關的副作用

波特的五力戰略工具駕馭破傷風類毒素疫苗市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解破傷風類毒素疫苗市場的外部影響

外部宏觀環境因素在塑造破傷風類毒素疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解破傷風類毒素疫苗市場的競爭格局

對破傷風類毒素疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣破傷風類毒素疫苗市場供應商的績效評估

FPNV 定位矩陣是評估破傷風類毒素疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製破傷風類毒素疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，破傷風類毒素疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 破傷風在世界各地廣泛傳播
      • 破傷風疫苗價格低廉且廣泛使用
    • 抑制因素
      • 因疫苗品質缺陷而導致產品召回的可能性
    • 機會
      • 政府關於宣傳和疫苗接種計劃的舉措
      • 改善各國的低溫運輸和醫療基礎設施
    • 任務
      • 與疫苗相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以疫苗類型分類的破傷風類毒素疫苗市場

  • 白喉和破傷風 (DT)
  • 白喉、破傷風和百日咳 (DTaP)
  • 破傷風、白喉、百日咳 (Tdap)

第7章依年齡分類的破傷風類毒素疫苗市場

  • 成人
  • 新生

第8章破傷風類毒素疫苗市場：依最終用戶分類

  • 診所
  • 醫院

第9章美洲破傷風類毒素疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區破傷風類毒素疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲破傷風類毒素疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AJ Vaccines A/S
  • Astellas Pharma Inc.
  • BB-NCIPD Ltd.
  • Bharat Biotech Ltd.
  • Bio Farma
  • Biological E. Limited
  • Dano Vaccines & Biologicals Pvt. Ltd.
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Vaccine Ltd.
  • MEDZEEL LIFESCIENCE
  • Merck & Co, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B1685377AB26

The Tetanus Toxoid Vaccine Market was valued at USD 5.58 billion in 2023, expected to reach USD 5.86 billion in 2024, and is projected to grow at a CAGR of 6.75%, to USD 8.83 billion by 2030.

The Tetanus Toxoid Vaccine is a crucial medical product defined by its ability to prevent tetanus, a potentially fatal bacterial infection characterized by muscle stiffness and spasms. The necessity of the vaccine stems from its role in safeguarding individuals who suffer cuts, wounds, or injuries that may expose them to Clostridium tetani, especially in healthcare facilities, military units, and during childbirth in developing regions. Its application extends to various public health programs, where it is crucial for routine immunizations and booster shots. The end-use scope of the vaccine encompasses hospitals, clinics, and community healthcare services, with a significant push towards increasing access in low- and middle-income countries. The current market for the tetanus toxoid vaccine is influenced by factors such as increasing global awareness of immunization, supportive government vaccination programs, and advancements in delivery technologies. Opportunities are blooming with the rising focus on combination vaccines that protect against multiple diseases, presenting avenues for manufacturers to innovate and reach diverse demographics. However, market growth faces challenges such as logistical issues in vaccine delivery, lack of awareness in remote areas, and vaccine hesitancy in certain populations. Additionally, the market is constrained by regulatory hurdles and pricing pressures amidst the need for affordable healthcare solutions. Despite these challenges, areas ripe for innovation include single-dose vaccines, improved cold chain technologies, and digitally controlled delivery systems that enhance efficiency and coverage. The nature of the market tilts towards a stable yet resilient growth pattern, driven by public health priorities and collaborations with non-governmental organizations to boost inoculation rates. Businesses stand to gain by investing in educational campaigns and developing cost-effective, easy-to-administer vaccines for broader reach and heightened public acceptance.

KEY MARKET STATISTICS
Base Year [2023] USD 5.58 billion
Estimated Year [2024] USD 5.86 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 6.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tetanus Toxoid Vaccine Market

The Tetanus Toxoid Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant prevalence of tetanus worldwide
    • Low cost and wide availability of tetanus vaccine
  • Market Restraints
    • Potential product recall due to vaccine quality defects
  • Market Opportunities
    • Government initiatives for awareness and immunization programs
    • Improving cold chain and healthcare infrastructure across countries
  • Market Challenges
    • Side effects associated with vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Tetanus Toxoid Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tetanus Toxoid Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tetanus Toxoid Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tetanus Toxoid Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tetanus Toxoid Vaccine Market

A detailed market share analysis in the Tetanus Toxoid Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tetanus Toxoid Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tetanus Toxoid Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tetanus Toxoid Vaccine Market

A strategic analysis of the Tetanus Toxoid Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tetanus Toxoid Vaccine Market, highlighting leading vendors and their innovative profiles. These include AJ Vaccines A/S, Astellas Pharma Inc., BB-NCIPD Ltd., Bharat Biotech Ltd., Bio Farma, Biological E. Limited, Dano Vaccines & Biologicals Pvt. Ltd., GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd., Incepta Vaccine Ltd., MEDZEEL LIFESCIENCE, Merck & Co, Inc., Panacea Biotec Limited, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Tetanus Toxoid Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), and Tetanus, Diphtheria and Pertussis (Tdap).
  • Based on Age, market is studied across Adults and Neonatal.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of tetanus worldwide
      • 5.1.1.2. Low cost and wide availability of tetanus vaccine
    • 5.1.2. Restraints
      • 5.1.2.1. Potential product recall due to vaccine quality defects
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives for awareness and immunization programs
      • 5.1.3.2. Improving cold chain and healthcare infrastructure across countries
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tetanus Toxoid Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Diphtheria and Tetanus (DT)
  • 6.3. Diphtheria,Tetanus, and Pertussis (DTaP)
  • 6.4. Tetanus, Diphtheria and Pertussis (Tdap)

7. Tetanus Toxoid Vaccine Market, by Age

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Neonatal

8. Tetanus Toxoid Vaccine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Tetanus Toxoid Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tetanus Toxoid Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tetanus Toxoid Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AJ Vaccines A/S
  • 2. Astellas Pharma Inc.
  • 3. BB-NCIPD Ltd.
  • 4. Bharat Biotech Ltd.
  • 5. Bio Farma
  • 6. Biological E. Limited
  • 7. Dano Vaccines & Biologicals Pvt. Ltd.
  • 8. GlaxoSmithKline PLC
  • 9. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 10. Incepta Vaccine Ltd.
  • 11. MEDZEEL LIFESCIENCE
  • 12. Merck & Co, Inc.
  • 13. Panacea Biotec Limited
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. TETANUS TOXOID VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. TETANUS TOXOID VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TETANUS TOXOID VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TETANUS TOXOID VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA AND TETANUS (DT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA,TETANUS, AND PERTUSSIS (DTAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY TETANUS, DIPHTHERIA AND PERTUSSIS (TDAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY NEONATAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023